tiprankstipranks
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
US Market
Holding GLUE?
Track your performance easily

Monte Rosa Therapeutics (GLUE) Ownership - Who Owns Monte Rosa Therapeutics?

266 Followers

Monte Rosa Therapeutics (GLUE) Ownership Overview

21.76%20.22%39.96%7.50%10.56%
21.76% Insiders
39.96% Other Institutional Investors
7.50% ETFs
10.56% Public Companies and
Individual Investors
The ownership structure of Monte Rosa Therapeutics (GLUE) stock is a mix of institutional, retail, and individual investors. Approximately 67.67% of the company’s stock is owned by Institutional Investors, 21.76% is owned by Insiders, and 10.56% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 30, 2024
xxxxxxxxxxxxx
$1489973
Sep 24, 2024
xxxxxxxxxxxxx
$7384330
Sep 13, 2024
xxxxxxxxxxxxx
$3404761
Jul 09, 2024
xxxxxxxxxxxxx
$6166

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$176060

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
7,692,298Insider12.52%64,307,611
5,652,922Insider9.20%47,258,428
4,916,095Institution8.00%41,098,554
3,418,333Institution5.56%28,577,264
2,441,190Institution3.97%20,408,348
2,209,590Institution3.60%18,472,172
1,595,831Institution2.60%13,341,147
1,472,331Institution2.40%12,308,687
1,336,920Institution2.18%11,176,651
982,758Institution1.60%8,215,857

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
3,418,333Institution5.56%28,577,264
2,209,590Institution3.60%18,472,172
1,336,920Institution2.18%11,176,651
982,758Institution1.60%8,215,857
952,900Institution1.55%7,966,244
868,208Institution1.41%7,258,219
852,355Institution1.39%7,125,688
416,599Institution0.68%3,482,768
352,859Institution0.57%2,949,901
145,799Institution0.24%1,218,880

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,350,106Institution2.20%11,475,901
1,086,780Institution1.77%9,085,481
683,679Institution1.11%5,811,272
390,815Institution0.64%3,267,213
218,959Institution0.36%1,819,549
186,976Institution0.30%1,589,296
152,530Institution0.25%1,296,505
95,513Institution0.16%798,489
64,411Institution0.10%535,255
60,693Institution0.10%321,673

FAQ

Who Owns Monte Rosa Therapeutics (GLUE)?
According to the latest TipRanks data, approximately 39.96% of the company's stock is held by institutional investors, 21.76% is held by insiders, and 10.56% is held by retail investors.
    What percentage of Monte Rosa Therapeutics (GLUE) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 39.96% of Monte Rosa Therapeutics (GLUE) stock is held by institutional investors.
      What percentage of Monte Rosa Therapeutics (GLUE) stock is held by retail investors?
      According to the latest TipRanks data, approximately 10.56% of Monte Rosa Therapeutics (GLUE) stock is held by retail investors.
        Who owns the most shares of Monte Rosa Therapeutics (GLUE)?
        Ali Behbahani owns the most shares of Monte Rosa Therapeutics (GLUE).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis